Update
$Inventiva(IVA.US$ Inventiva Resumes Screening In NATiV3, Phase III, Clinical Trial Evaluating Lanifibranor In NASH
Benzinga· 2 mins ago
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
Screening of patients is resuming in sites operating under central IRB in the US.
Other sites and countries are expected to resume screening and randomization activities progressively over the next weeks.
Last Patient First Visit is currently targeted for first half 2024.
Benzinga· 2 mins ago
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
Screening of patients is resuming in sites operating under central IRB in the US.
Other sites and countries are expected to resume screening and randomization activities progressively over the next weeks.
Last Patient First Visit is currently targeted for first half 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
